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Abstract: Background Very preterm infants are at high risk of death or severe morbidity. The objective
was to determine the significance of severe congenital heart defects (CHDs) for these risks. Methods
and Results This cohort study included infants from 10 countries born from 2007-2015 at 24 to 31
weeks’ gestation with birth weights <1500 g. Severe CHDs were defined by International Classification
of Diseases, Ninth Revision (ICD-9) and Tenth (ICD-10) codes and categorized as those compromising
systemic output, causing sustained cyanosis, or resulting in congestive heart failure. The primary outcome
was in-hospital mortality. Secondary outcomes were neonatal brain injury, necrotizing enterocolitis,
bronchopulmonary dysplasia, and retinopathy of prematurity. Adjusted and propensity score-matched
odds ratios (ORs) were calculated. Analyses were stratified by type of CHD, gestational age, and network.
A total of 609 (0.77%) infants had severe CHD and 76 371 without any malformation served as controls.
The mean gestational age and birth weight were 27.8 weeks and 1018 g, respectively. The mortality
rate was 18.6% in infants with CHD and 8.9% in controls (propensity score-matched OR, 2.30; 95%
CI, 1.61-3.27). Severe CHD was not associated with neonatal brain injury, necrotizing enterocolitis, or
retinopathy of prematurity, whereas the OR for bronchopulmonary dysplasia increased. Mortality was
higher in all types, with the highest propensity score-matched OR (4.96; 95% CI, 2.11-11.7) for CHD
causing congestive heart failure. While mortality did not differ between groups at <27 weeks’ gestational
age, adjusted OR for mortality in infants with CHD increased to 10.9 (95% CI, 5.76-20.70) at 31 weeks’
gestational age. Rates of CHD and mortality differed significantly between networks. Conclusions Severe
CHD is associated with significantly increased mortality in very preterm infants.
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Background-—Very preterm infants are at high risk of death or severe morbidity. The objective was to determine the significance of
severe congenital heart defects (CHDs) for these risks.
Methods and Results-—This cohort study included infants from 10 countries born from 2007–2015 at 24 to 31 weeks’ gestation with
birth weights <1500 g. Severe CHDs were defined by International Classification of Diseases, Ninth Revision (ICD-9) and Tenth (ICD-10)
codes and categorized as those compromising systemic output, causing sustained cyanosis, or resulting in congestive heart failure. The
primary outcome was in-hospital mortality. Secondary outcomes were neonatal brain injury, necrotizing enterocolitis, bronchopul-
monary dysplasia, and retinopathy of prematurity. Adjusted and propensity score–matched odds ratios (ORs) were calculated. Analyses
were stratified by type of CHD, gestational age, and network. A total of 609 (0.77%) infants had severe CHD and 76 371 without any
malformation served as controls. The mean gestational age and birth weight were 27.8 weeks and 1018 g, respectively. The mortality
rate was 18.6% in infants with CHD and 8.9% in controls (propensity score–matched OR, 2.30; 95% CI, 1.61–3.27). Severe CHD was not
associated with neonatal brain injury, necrotizing enterocolitis, or retinopathy of prematurity, whereas the OR for bronchopulmonary
dysplasia increased. Mortality was higher in all types, with the highest propensity score–matched OR (4.96; 95% CI, 2.11–11.7) for CHD
causing congestive heart failure. While mortality did not differ between groups at <27 weeks’ gestational age, adjusted OR for mortality
in infants with CHD increased to 10.9 (95% CI, 5.76–20.70) at 31 weeks’ gestational age. Rates of CHD and mortality differed
significantly between networks.
Conclusions-—Severe CHD is associated with significantly increased mortality in very preterm infants. ( J Am Heart Assoc.
2020;9:e015369. DOI: 10.1161/JAHA.119.015369.)
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P
reterm birth remains the most common cause of death in
children younger than 5 years.
1
In particular, those born
very preterm, ie, more than 8 weeks before their due date, face
a considerable risk of mortality.
2
To disentangle the effects of
prematurity from other causes of neonatal death, congenital
malformations have been excluded in many studies of preterm
mortality.
2–4
By this approach, however, the outcomes for
preterm infants with malformations have been left unstudied.
Birth defects are more common in the very preterm than in
the general newborn population, and congenital heart defects
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(CHDs) are among the most common types.
5–8
The majority
are minor and are associated with an excellent prognosis, but
severe CHDs are associated with excess mortality in term
infants.
9–11
Less is known about the outlook for very preterm
infants with CHDs. Previous studies have indicated signifi-
cantly lower survival in preterm infants with CHDs than in
those without CHDs.
7,9,12–16
Limitations of these studies
include older birth cohorts (from 1985 to 2005), low numbers
(from 0 to 149 infants born very preterm) with mixed types of
CHDs, and little or no information on the association with
gestational age (GA) <32 weeks.7,9,12–15 Three larger studies
including live-born infants with birth weights <1500 g
reported mortality rates of 44% to 55%
16,17
and an increased
risk for necrotizing enterocolitis (NEC) in infants with severe
CHD.
18
The reports on mortality (infants born in 1997–2012)
included significant proportions of infants with CHDs who
were untreated with antenatal corticosteroids (29–35%), who
were outborn (21–51%), who were small for GA (42%),17 and





—all factors that may affect mortality inde-
pendent of CHDs.
19–21
Moreover, the mean GA was 28 to
30 weeks and the relationship between CHD and neonatal
outcome at the lowest GA remains to be clarified. Finally,
there are no reports available from outside of the United
States.
The objective of this study was to determine neonatal
outcomes for a contemporary cohort of very preterm infants
born with severe and isolated CHD by type of CHD, by
gestational week at birth, and by country of birth. Our main
hypotheses were that severe CHD would be associated with
significantly increased risks of mortality and morbidity in
very preterm infants, particularly among those with the
lowest GA, and that neonatal outcomes would vary between
countries.
Methods
Individual data will not be made available to other researchers
for purposes of reproducing the results or replicating the
procedures because the institutional review boards only
permitted aggregated data to be publicly available or
published. Analytic methods, however, are presented in this
article to assist other researchers in reproducing the results
or replicating the procedures.
Setting
The study used data from the International Network for
Evaluation of Outcomes in Neonates (iNeo), ie, from neonatal
networks in 10 high-resource countries: Australia, New
Zealand, Canada, Finland, Israel, Italy, Japan, Spain, Sweden,
and Switzerland.
22
The participating networks and the iNeo
Coordinating Centre at the Maternal-Infant Care Research
Centre, Mount Sinai Hospital in Toronto, Canada, each
obtained data sharing agreements and research ethics review
and approval for data collection, transfer, and analyses from
the local, national institutional ethics committees. Because of
the retrospective nature of the study, informed consent from
parents was waived.
Data Sources
Individual-level data from the following neonatal networks
were included: Australia and New Zealand Neonatal Network
(ANZNN), Canadian Neonatal Network (CNN),
23
FinMB (Fin-
nish Medical Birth Register), Neonatal Research Network of
Japan (NRNJ),
24
Israel Neonatal Network (INN),
25
Tuscany
Neonatal Network (TIN-Toscane online), Spanish Neonatal
Network (SEN1500), SNQ (Swedish Neonatal Quality Regis-
ter),
26
and Swiss Neonatal Network (SwissNeoNet). Previous
reports provide details of the proportion of neonates in this
data set out of the total number of neonates born in each
country.
27
Based on a consensus between all iNeo partici-
pants, data collection was standardized and included infor-
mation on maternal and obstetric variables, neonatal
characteristics, treatments, and outcomes. Diagnoses were
classified according to the Ninth and Tenth versions of the




The study population included all singleton infants admitted to
neonatal units between 2007 and 2015 who were very
preterm (between 24 and 31 weeks’ gestation) and had birth
weights <1500 g. The database did not hold information on
abortions or stillbirths. In addition, delivery room deaths were
not consistently captured across networks and were therefore
Clinical Perspective
What Is New?
• Irrespective of type of heart defect, very preterm infants
with severe congenital heart defects have higher odds for
mortality, but not for neonatal brain injury, necrotizing
enterocolitis, or treated retinopathy of prematurity, than
peers without severe congenital heart defects.
What Are the Clinical Implications?
• Although the outlook for very preterm infants with severe
congenital heart defects remains poorer than in peers
without congenital heart defects, 4 of 5 of the affected
infants survive the neonatal period and without an increased
risk for added major neonatal morbidity.
DOI: 10.1161/JAHA.119.015369 Journal of the American Heart Association 2













































excluded. Multiple pregnancies and neonates with major
congenital malformations in addition to CHD were also
excluded.
Exposure
In a first step, infants with a diagnosis of any CHDwere identified
in the iNeo database by a search strategy using ICD-9 codes 745
to 747 or ICD-10 codes Q200-Q262. Second, infants with minor
CHDs (n=1928); CHD associated with a chromosomal aberration
(trisomy 21 [n=9], trisomy 13 or 18 [n=4], or other trisomy or
monosomy [n=2]); or additional severe malformations (nervous
[ICD-10 codes Q00–05], digestive [Q39, 41, 42, 44, and 79], or
urinary [Q60–61] syndromes [Q74–78, Q86, Q8726, Q894]
[n=33 infants total]) were excluded. The study group consisted of
the remaining very preterm infants without chromosomal
anomaly who had isolated, severe CHD (main exposure).
Differentiation between nonsevere and severe CHDs was
performed using the European network of population-based
registries for the epidemiological surveillance of congenital
anomalies (EUROCAT) criteria.
29
A patent ductus arteriosus was
not considered as a CHD in this context. A third and final step
included the Vermont Oxford Network (VON) categorization
18
of
severeCHDsbymanifestation: category A compriseddefects that
primarily compromised systemic output (critical aortic stenosis,
coarctation of the aorta, hypoplastic left heart syndrome, and
interrupted aortic arch); category B comprised defects that
created sustained cyanosis (transposition of the great vessels,
tetralogy of Fallot, critical pulmonic stenosis, pulmonary atresia,
tricuspid atresia, and total anomalous pulmonary venous return);
and categoryC comprised diagnoses resulting in congestive heart
failure (CHF) and pulmonary overcirculation (such as complete
atrioventricular canal, double outlet right ventricle, truncus
arteriosus, and other single ventricle physiology).
Outcomes
The primary outcome was mortality. Secondary outcomes
included a composite of mortality and major neonatal
morbidity, and major morbidities analyzed as separate
outcomes. Major neonatal morbidity was defined as ≥1 of
the following diagnoses: intraventricular hemorrhage grade 3
to 4
30
or cystic periventricular leukomalacia
31
; NEC stages 2
or 3
32
; bronchopulmonary dysplasia (defined as oxygen
requirement, with or without mechanical respiratory support,
at 36 weeks of postmenstrual age or at time of transfer to
level 2 unit)
33
; and treated retinopathy of prematurity.
34
Covariates
Covariates and potential confounders included advanced mater-
nal age (≥35 years) at delivery of the infant; hypertensive disorder
of pregnancy (chronic hypertension, gestational hypertension,
preeclampsia, eclampsia, or hemolysis, elevated liver enzymes,
low platelet count syndrome); any treatment with antenatal
corticosteroids; mode of delivery; delivery outside a tertiary
center; GA; infant sex; birth weight z score; and country of birth.
Statistical Analyses
Maternal and infant characteristics and outcomes were
compared between neonates with and without severe CHD.
Frequencies (percentages) or means (SDs) were reported.
Differences between groups were assessed with Pearson chi-
square tests and Student t tests for categorical variables and
continuous variables, respectively. Univariate and multivari-
able logistic analyses were applied for the primary and
secondary outcomes. Odds ratios (ORs) with 95% CIs were
estimated. The analyses were stratified by CHD manifestation,
GA, and network. Finally, propensity score (PS) matching was
applied for analysis. The PS for 2 groups was estimated using
multivariate logistic regression stratified by network. Match-
ing between infants with CHD and infants without CHD was
performed using the SAS macro match.sas and was based on
a caliper width of 0.2 times the SD of the logit-transformed
PS. Within each matched sample, covariates were tested for
balance using paired t tests for continuous variables and
McNemar tests for categorical covariates. The association
between severe CHD and neonatal outcome in each matched
sample was examined by using generalized estimating
All admissions 
(24-31 gestaonal weeks; <1500 g):
n=78,956
Severe CHD, chromosomal 
(n=15)
Severe CHD with associated 
malformaon (n=33)
Minor CHD (n=1,928)
Resulng in congesve heart 
failure (n=103)




Non-chromosomal, isolated, severe 
CHD: n=609 (rate=7.7/1,000) 
No malformaon (n=76,371)
Figure 1. Flow chart: inclusion and severe congenital heart defects
(CHDs) by their manifestation in very preterm, singleton infants.
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equations with logit linkage and unstructured correlation, and
ORs with 95% CIs were estimated. All analyses were
conducted using SAS 9.4 (SAS Institute Inc) with a 2-sided
significance level of 0.05.
Results
Between 2007 and 2015, there were 78 956 singleton very
preterm infants in the database, 76 371 (96.7%) of whom had
no malformation and 2585 (3.3%) of whom had a diagnosis of
any CHD. Of these, 1928 (2.4%) had nonsevere CHDs, and
609 (0.77%) neonates had nonchromosomal, isolated, severe
CHDs. The distribution of the 3 types of severe CHDs is
depicted in Figure 1.
Baseline characteristics are reported in Table 1. In com-
parison with infants without CHDs, infants with severe CHDs
were more frequently treated with antenatal corticosteroids,
were more often outborn and small for GA, and had a larger
proportion with Apgar scores <7 at 5 minutes.
Table 1. Maternal, Obstetric, and Neonatal Characteristics of Very Preterm Infants With and Without Nonchromosomal, Isolated,
Severe CHDs
Infants With Severe CHD (N=609) Infants Without CHD (N=76 371) P Value
Maternal characteristics
Maternal age ≥35 y, n/N (%) 118/448 (26.3) 14 082/59 110 (23.8) 0.21
Hypertensive disorders of pregnancy*, n/N (%) 136/561 (24.2) 16 474/69 194 (23.8) 0.81
Antenatal corticosteroids, n/N (%) 485/599 (81.0) 57 441/74 536 (77.1) 0.02
Cesarean section, n/N (%) 431/608 (70.9) 51 113/75 698 (67.5) 0.08
Neonatal characteristics
Apgar score <7 at 5 min, n/N (%) 176/598 (29.4) 18 752/74 855 (25.1) 0.01
Gestational age, n/N (%)
28–31 wk 359/609 (59.0) 43 377/76 371 (56.8) 0.29
<28 wk 250/609 (41.0) 32 994/76 371 (43.2)
Males, n/N (%) 302/609 (49.6) 39 987/76 337 (52.4) 0.17
Birth weight, mean (SD) 0.12
Grams 1018 (279) 1035 (271) <0.01
z score 0.44 (1.07) 0.25 (0.95)
Small for gestational age, n/N (%) 139/609 (22.8) 10 948/76 336 (14.3) <0.01
Outborn, n/N (%) 75/609 (12.3) 7321/76 343 (9.6) 0.02
CHD indicates congenital heart defect; n, number in group; N, total number in category.
*Hypertension in pregnancy includes gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome.







n/N (%) Crude OR (95% CI)
Model 1 Adjusted
OR (95% CI)*
Model 2 PS Score–Matched
OR (95% CI)†
Mortality 113/609 (18.6) 6815/76 371 (8.9) 2.33 (1.89–2.86) 2.46 (1.95–3.11) 2.30 (1.61–3.27)
Mortality or major morbidity‡ 313/583 (53.7) 26 616/72 232 (36.9) 1.99 (1.69–2.34) 2.67 (2.21–3.24) 1.91 (1.53–2.38)
Severe brain injury§ 67/580 (11.6) 6868/72 033 (9.5) 1.24 (0.96–1.60) 1.26 (0.96–1.64) 1.10 (0.77–1.58)
Necrotizing enterocolitis 41/606 (6.8) 3595/75 172 (4.8) 1.45 (1.05–1.99) 1.22 (0.88–1.69) 1.21 (0.75–1.95)
Bronchopulmonary dysplasia 185/504 (36.7) 14 680/67 979 (21.6) 2.11 (1.76–2.53) 2.64 (2.14–3.27) 1.82 (1.41–2.34)
Treated retinopathy of prematurity 40/609 (6.6) 5271/76 344 (6.9) 0.95 (0.69–1.31) 1.54 (1.09–2.18) 1.27 (0.81–1.99)
CHD indicates congenital heart defect.
*Model 1: adjusted for gestational age, sex, birth weight z score, network, antenatal corticosteroids, mode of delivery, and outborn.
†
Model 2: propensity score (PS)–matched odds ratios (ORs), stratified by network.
‡
Major neonatal morbidity: intraventricular hemorrhage grade 3 to 4, cystic periventricular leukomalacia, retinopathy of prematurity treatment, or bronchopulmonary dysplasia.
§
Severe brain injury: intraventricular hemorrhage grade 3 or 4 or cystic periventricular leukomalacia.
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In-hospital mortality was 18.6% (95% CI, 15.5–21.7%) in
infants with severe CHDs and 8.9% (95% CI, 8.7–9.1%) in
infants without any CHD (P<0.001). The proportion of infants
with the composite outcome in-hospital mortality or major
neonatal morbidity was 53.7% (95% CI, 49.7–57.8%) in those
with CHDs and 36.9% (95% CI, 36.5–37.2%) in controls
(P<0.001). Infants with CHDs had significantly higher rates of
bronchopulmonary dysplasia defined as oxygen dependency
at 36 weeks of postmenstrual age, but they did not differ
from infants without CHD with regards to odds for severe
neonatal brain injury (intraventricular hemorrhage grade 3 or
4 or cystic periventricular leukomalacia), NEC, or treated
retinopathy of prematurity. After adjustments and PS match-
ing, the ORs for mortality and the composite outcome
changed marginally from the unadjusted models (Table 2).
The highest odds for mortality (PS-matched OR, 4.96; 95%
CI, 2.11–11.7) and for the composite outcome (PS-matched
OR, 2.82; 95% CI, 1.61–4.94) were seen in infants with CHDs
manifesting primarily as CHF. The lowest increase in odds for
mortality (PS-matched OR, 1.84; 95% CI, 1.20–2.83]) was
seen in infants with CHDs manifesting as sustained cyanosis
(Tables 3 through 5).
In infants of <27 weeks GA, in-hospital mortality did not
differ between infants with (37/165=22.4%; 95% CI, 16.1–
28.8%) and without (4653/22 670=20.5%; 95% CI, 20.0–
21.0%) severe CHD. From27 weeks’GA and upwards, mortality
decreased significantly more slowly in infants with CHD than in
those without; and at 31 weeks’ GA, the in-hospital mortality
was still 15.1% (95% CI, 7.6–22.7%) in infants with CHD but had
decreased to 1.5% (95% CI, 1.2–1.7%) in those without CHD
Table 3. Odds for In-Hospital Mortality and for Major Neonatal Morbidity for Category A: Very Preterm Infants With CHDs
Compromising Systemic Output
Infants With Severe CHD (N=77),
n/N (%)
Infants Without CHD (N=76 371),
n/N (%) Crude OR (95% CI)
Model 1 Adjusted
OR (95% CI)*
Model 2 PS Score–
Matched OR (95% CI)
†
In-hospital mortality 16/77 (20.8) 6815/76 371 (8.9) 2.68 (1.54–4.65) 3.46 (1.85–6.48) 2.26 (0.97–5.30)
In-hospital mortality or
major neonatal morbidity‡
40/75 (53.3) 26 616/72 232 (36.9) 1.96 (1.24–3.08) 3.51 (2.10–5.88) 2.01 (1.08–3.72)
IVH grade 3 or 4 or cPVL 13/75 (17.3) 6868/72 033 (9.5) 1.99 (1.09–3.62) 2.27 (1.21–4.25) 1.95 (0.73–5.21)
NEC 5/77 (6.5) 3595/75 172 (4.8) 1.38 (0.56–3.42) 1.23 (0.49–3.08) 1.69 (0.38, 7.60)
BPD 17/62 (27.4) 14 680/67 979 (21.6) 1.37 (0.78–2.40) 1.77 (0.92, 3.40) 1.69 (0.82–3.46)
ROP (treated) 4/77 (5.2) 5271/76 344 (6.9) 0.74 (0.27–2.02) 2.01 (0.70–5.75) 1.00 (0.23–4.31)
BPD indicates bronchopulmonary dysplasia; CHD, congenital heart defect; cPVL, cystic periventricular leukomalacia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; OR,
odds ratio; PS, propensity score; ROP, retinopathy of prematurity.
*Model 1: adjusted for gestational age, sex, birth weight z-score, network, antenatal corticosteroids, mode of delivery, and outborn.
†
Model 2: propensity score (PS)-matched odds ratios, stratified by network.
‡
Major neonatal morbidity: intraventricular hemorrhage grade 3-4, cystic periventricular leukomalacia, retinopathy of prematurity treatment, or bronchopulmonary dysplasia.





Infants Without CHD (N=76 371),
n/N (%) Crude OR (95% CI)
Model 1 Adjusted
OR (95% CI)*
Model 2 PS Score–Matched
OR (95% CI)
†
In-hospital mortality 66/429 (15.4) 6815/76 371 (8.9) 1.86 (1.43–2.42) 1.86 (1.39–2.50) 1.84 (1.20–2.83)
In-hospital mortality or major
neonatal morbidity‡
211/407 (51.8) 26 616/72 232 (36.9) 1.85 (1.52–2.24) 2.28 (1.81–2.86) 1.71 (1.32–2.22)
IVH grade 3 or 4 or cPVL 43/407 (10.6) 6868/72 033 (9.5) 1.12 (0.82–1.54) 1.15 (0.83–1.61) 1.11 (0.71–1.75)
NEC 25/427 (5.9) 3595/75 172 (4.8) 1.24 (0.83–1.86) 1.04 (0.69–1.58) 1.08 (0.59–1.98)
BPD 138/368 (37.5) 14 680/67 979 (21.6) 2.18 (1.76–2.69) 2.55 (1.99–3.26) 1.73 (1.29–2.32)
ROP (treated) 30/429 (7.0) 5271/76 344 (6.9) 1.01 (0.70–1.47) 1.54 (1.03–2.31) 1.39 (0.81–2.38)
BPD indicates bronchopulmonary dysplasia; CHD, congenital heart defect; cPVL, cystic periventricular leukomalacia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; OR,
odds ratio; PS, propensity score; ROP, retinopathy of prematurity.
*Model 1: adjusted for gestational age, sex, birth weight z-score, network, antenatal corticosteroids, mode of delivery, and outborn.
†
Model 2: propensity score (PS)-matched odds ratios, stratified by network.
‡
Major neonatal morbidity: intraventricular hemorrhage grade 3-4, cystic periventricular leukomalacia, retinopathy of prematurity treatment, or bronchopulmonary dysplasia.
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(Figure 2) (adjusted OR, 10.9; 95% CI, 5.76–20.7). Driven by
mortality, a similar trend was observed for the composite
outcome stratified on GA (Table 6).
The overall prevalence of severe CHD in the iNeo database
was 7.7 per 1000 infants, with a significant network variation
from low (1/941=1.06 per 1000 infants in TuscanNN and 70/
22 578=3.1 per 1000 infants in NRNJ) to high (152/
10 384=14.6 per 1000 infants in CNN and 52/3139=16.6
per 1000 infants in SNQ). The increase in odds for the
composite outcome in infants with CHD compared with
controls also varied significantly between networks, with
adjusted ORs for mortality or major neonatal morbidity (in
networks reporting at least 10 infants with CHD who had the
composite outcome) ranging from 1.85 (95% CI, 1.26–2.70) in
Canada to 29.3 (95% CI, 5.84–146) in Switzerland (Table 7).
Survival data by type of severe CHD is presented in
Table 8.
Discussion
This study has several important findings. First, very preterm
infants with isolated, nonchromosomal, severe CHD exhibited
2 to 3 times higher odds for in-hospital mortality than infants
without CHD. Second, infants with CHD also had higher odds
for oxygen dependency at 36 weeks’ postmenstrual age,
whereas proportions with major neonatal brain injury, NEC,
and treated retinopathy of prematurity did not differ signif-
icantly from infants without CHD. Third, the largest group, ie,
those with CHD creating sustained cyanosis, had the most
favorable outcomes, whereas CHD creating CHF was associ-
ated with the poorest survival. Fourth, while mortality declined
with each week of increasing GA in infants without CHD, it
remained high in infants with CHD irrespective of GA. Finally,
rates and outcomes of severe CHD in very preterm infants
varied 10-fold between networks and countries.
Strengths and Limitations
Given the low prevalence of severe CHD, different types of
CHD, and the comparatively low incidence of very preterm
birth, large sample sizes are required to accurately estimate
neonatal risks. iNeo is a collaboration between neonatal
networks from high income countries.
35
With detailed infor-
mation on more than 150 000 infants, the database offers a
unique opportunity to assess the impact of rare exposures on
rare outcomes. This is the first study of rates of severe CHDs
outside of the United States and of associated mortality and
morbidity risks in very preterm infants by each gestational
Table 5. Odds for In-Hospital Mortality and Major Neonatal Morbidity for Category C: Very Preterm Infants With CHDs Resulting in
CHF




n/N (%) Crude OR (95% CI)
Model 1 Adjusted
OR (95% CI)*
Model 2 PS Score–
Matched OR (95% CI)
†
In-hospital mortality 31/103 (30.1) 6815/76 371 (8.9) 4.39 (2.88–6.70) 5.05 (3.10–8.24) 4.96 (2.11–11.7)
In-hospital mortality or major
neonatal morbidity‡
62/101 (61.4) 26 616/72 232 (36.9) 2.72 (1.82–4.07) 4.17 (2.60–6.67) 2.82 (1.61–4.94)
IVH grade 3–4 or cPVL 11/98 (11.2) 6868/72 033 (9.5) 1.20 (0.64–2.24) 1.06 (0.55–2.03) 1.03 (0.44–2.44)
NEC 11/102 (10.8) 3595/75 172 (4.8) 2.41 (1.29–4.50) 1.99 (1.05–3.79) 1.41 (0.54–3.65)
BPD 30/74 (40.5) 14 680/67 979 (21.6) 2.48 (1.56–3.94) 4.22 (2.49–7.16) 2.45 (1.22–4.89)
ROP (treated) 6/103 (5.8) 5271/76 344 (6.9) 0.83 (0.37–1.90) 1.29 (0.53–3.17) 1.00 (0.37–2.68)
CHD indicates congenital heart defect; CHF, congestive heart failure; NEC, necrotizing enterocolitis.
*Model 1: adjusted for gestational age, sex, birth weight z score, network, antenatal corticosteroids, mode of delivery, and outborn.
†
Model 2: propensity score (PS)–matched odds ratios (ORs), stratified by network.
‡





























Figure 2. Mortality rates (lines) by gestational age among very
preterm infants with or without severe congenital heart defects
(CHDs). aOR (grey bars) indicates adjusted odds ratio for
mortality.
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week and by network. It also provides the most contemporary
estimation of neonatal outcomes in very preterm infants with
severe CHD. Information on obstetrical and neonatal variables
was available, and data were collected according to common
preset definitions and standardized protocols, limiting infor-
mation bias. Mortality and morbidity were adjusted for GA and
Table 6. Mortality and Composite Outcome of Mortality or Major Neonatal Morbidity Among Very Preterm Infants With or Without
Severe CHDs by Gestational Age
Gestational Age, wk Infants With Severe CHD, n/N (%) Infants Without CHD, n/N (%) Crude OR (95% CI) Adjusted OR (95% CI)*
Mortality
24 7/37 (18.9) 1897/5885 (32.2) 0.49 (0.22–1.12) 0.36 (0.15–0.87)
25 18/58 (31.0) 1567/7602 (20.6) 1.73 (0.99–3.03) 1.63 (0.90–2.94)
26 12/71 (16.9) 1189/9183 (13.0) 1.37 (0.73–2.55) 1.16 (0.61–2.22)
27 18/84 (21.4) 855/10 324 (8.3) 3.02 (1.79–5.11) 2.82 (1.62–4.90)
28 18/93 (19.4) 570/12 024 (4.7) 4.82 (2.86–8.12) 3.43 (1.99–5.93)
29 11/88 (12.5) 391/12 366 (3.2) 4.38 (2.31–8.30) 3.52 (1.81–6.84)
30 16/92 (17.4) 229/10 968 (2.1) 9.87 (5.67–17.2) 9.29 (5.13–16.8)
31 13/86 (15.1) 117/8019 (1.5) 12.0 (6.49–22.3) 10.9 (5.76–20.7)
Composite outcome: mortality or major neonatal morbidity†
24 27/36 (75.0) 4825/5749 (83.9) 0.57 (0.27–1.23) 0.53 (0.25–1.16)
25 43/57 (75.4) 5210/7319 (71.2) 1.24 (0.68–2.28) 1.26 (0.68–2.36)
26 51/68 (75.0) 4963/8778 (56.5) 2.31 (1.33–4.00) 2.46 (1.39–4.33)
27 46/82 (56.1) 4028/9861 (40.9) 1.86 (1.19–2.87) 2.03 (1.28–3.22)
28 44/88 (50.0) 3281/11 443 (28.7) 2.49 (1.63–3.79) 2.31 (1.49–3.58)
29 35/83 (42.2) 2282/11 645 (19.6) 2.99 (1.93–4.64) 2.87 (1.82–4.53)
30 36/87 (41.4) 1346/10 138 (13.3) 4.61 (3.00–7.09) 4.39 (2.77–6.95)
31 31/82 (37.8) 681/7299 (9.3) 5.91 (3.75–9.29) 5.68 (3.53–9.15)
CHD indicates congenital heart defect; n, number in group; N, number in category; OR, odds ratio.
*Adjusted for antenatal corticosteroids, mode of delivery, sex, outborn, birth weight z score, and network.
†
Major neonatal morbidity: intraventricular hemorrhage grade 3 or 4, cystic periventricular leukomalacia, retinopathy of prematurity treatment, or bronchopulmonary dysplasia.
Table 7. Composite* Outcome for Very Preterm Infants With and Without Severe CHDs by Neonatal Network
Neonatal Network Infants With Severe CHD, n/N (%) Infants Without CHD, n/N (%) Crude OR (95% CI) Adjusted OR (95% CI)
†
ANZNN 65/109 (59.6) 5539/14 371 (38.5) 2.36 (1.60–3.46) 3.48 (1.57–3.91)
CNN 67/152 (44.1) 3401/10 232 (33.2) 1.58 (1.15–2.19) 1.85 (1.26–2.70)
FinMBR 2/5 (40.0) 345/1004 (34.4) 1.27 (0.21–7.66) 0.96 (0.14–6.68)
INN 26/52 (50.0) 1793/5407 (33.2) 2.02 (1.17–3.48) 3.75 (1.99–7.07)
NRNJ 47/70 (67.1) 8673/22 508 (38.5) 3.26 (1.98–5.37) 5.97 (3.36–10.6)
SEN1500 67/130 (51.5) 4652/11 498 (40.5) 1.57 (1.11–2.21) 2.25 (1.51–3.34)
SNQ 29/52 (55.8) 1043/3087 (33.8) 2.47 (1.42–4.29) 3.00 (1.56–5.77)
SwissNeoNet 10/12 (83.3) 904/3184 (28.4) 12.6 (2.76–57.7) 29.3 (5.84–146.5)
TuscanNN 0/1 (0) 266/941 (28.3) NA NA
All networks 313/583 (53.7) 26 616/72 232 (36.9) 1.99 (1.69–2.34) 2.65 (2.19–3.21)
ANZNN indicates Australia and New Zealand Neonatal Network; CHD, congenital heart defect; CNN, Canadian Neonatal Network; FinMBR, Finnish Medical Birth Registry; INN, Israel
Neonatal Network; N, number in category; n, number in group; NRNJ, Neonatal Research Network of Japan; OR, odds ratio; SEN1500, Spanish Neonatal Network; SNQ, Swedish Neonatal
Quality Register; SwissNeoNet, Swiss Neonatal Network; TuscanNN, Tuscany Neonatal Network (Italy).
*Mortality or major neonatal morbidity (defined as intraventricular hemorrhage grade 3 or 4, cystic periventricular leukomalacia, retinopathy of prematurity treatment, or
bronchopulmonary dysplasia).
†
Adjusted for antenatal corticosteroids, mode of delivery, gestational age, sex, outborn, and birth weight z score.
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for other factors that are known to influence outcomes. PS
matching added to the robustness of the analyses.
This study also has limitations. The data set did not contain
information on antenatal screening or diagnosis of CHD, or on
terminations of pregnancy and fetal deaths. Including only live
births and not all very preterm births may have led to a
conservative bias in estimating mortality rates and risks
associated with severe CHD. The iNeo database—like the
VON—only included information on infants with birth weights
of ≤1500 g. This means that some appropriate- and large-for-
gestational-age infants born at 30 to 31 weeks’ GA were
excluded from the analysis, which could have contributed to a
larger proportion of small-for-GA infants in this GA span.
However, all analyses were adjusted for birth weight z scores.
Although several of the networks were population-based,
others only included data from hospitals with level III neonatal
intensive care units and so some outborn babies may have
escaped reporting. The database did not contain information
on specific surgical procedures for CHD, potential redirection
of care after a postnatal diagnosis of CHD or on organization
of care in the 390 hospitals in the 10 iNeo countries. This
limits the applicability of the overall associations in counseling
families and guiding medical decisions. However, presenting
outcome data by type of CHD, for each gestational week and
by geographical region, this study provides a higher resolution
than previous work. Despite accounting for several important
confounders, we cannot exclude the possibility of residual
confounding by unmeasured or unknown confounders. The
ICD codes were not validated against other databases or
medical records. In adults, administrative data sets utilizing




were mainly a problem for minor CHD. The current study only
included severe CHD diagnosed in infancy by expert pediatric
cardiologists. Accordingly, significant misclassification should
not be a problem in this study. Finally, survival was confined
to hospital discharge and did not extend beyond hospital stay.
Comparison With Other Studies
The rate of severe CHD in very preterm infants reported here
(7.7 per 1000) is in the same range as that reported from the
VON (8.9 per 1000).
17
Another US study from the Pediatrix
Medical Group reported an annual rate of 2.2 per 1000 for
nonchromosomal major CHD in very preterm infants.
16
This
rate is similar to that in the general newborn population,
where it is reported to be 2.0 per 1000.
10
Different CHD rates
may reflect differences in the set of CHD diagnoses and
denominators (live born or neonatal intensive care unit
admissions only) chosen. High rates of severe CHD in our
study and reported by VON may also reflect referral bias, as
these networks consist of a high proportion of tertiary
centers. A higher prevalence of cardiovascular malformations
in preterm infants than in term infants has been previously
reported.
9
So far, it has been difficult to explain the excess
CHDs in preterm infants. Although ascertainment bias could
be a contributing factor because of more frequent postnatal
echocardiographic assessments in very preterm than in term
infants, this explanation could only be valid for minor CHDs
without clinical manifestations in the neonatal period.
In the majority of infants with CHD, the CHD manifested as
sustained cyanosis. Similar or lower proportions of cyanotic
Table 8. Mortality by Type of Severe CHD









Aortic valve stenosis 746.3 Q230 18/55 (32.7)
Coarctation of the aorta,
IAA
747.1 Q251 6/37 (16.2)
HLHS 746.7 Q234 6/11 (54.6)
Aortic atresia, stenosis,
hypoplasia
747.22 Q252 3/7 (42.9)
Congenital mitral
insufficiency
746.6 Q233 1/7 (14.3)
Congenital mitral stenosis 746.5 Q232 1/3 (33.3)
Category B (defects that
create sustained cyanosis)
66/429 (15.4)
Tetralogy of Fallot 745.2 Q213 12/118 (10.2)
TGA 745.1 Q203 18/55 (32.7)
Pulmonary valve atresia 746.01;
746.02
Q220 2/22 (9.1)
Pulmonary artery atresia 743.7 Q255 1/7 (14.3)
Epstein anomaly 746.2 Q225 3/5 (60.0)
Tricuspid atresia 746.1 Q224 1/1 (100)
TAPVR 747.41 Q262 1/1 (100)
HRHS (Missing) Q226 0/2 (0)
Category C (diagnoses
resulting in CHF and
pulmonary overcirculation)
31/103 (30.1)
AVSD 745.69 Q212 17/58 (29.3)
Truncus arteriosus 745.00 Q200 9/32 (28.1)
Double outlet right
ventricle
745.11 Q201 6/17 (35.3)
Other single ventricle 745.3 Q204 3/5 (60.0)
AVSD indicates atrioventricular septal defect; CHD, congenital heart defect; CHF,
congestive heart failure; HLHS, hypoplastic left heart syndrome; HRHS, hypoplastic right
heart syndrome; IAA, interrupted aortic arch; ICD-9, International Classification of
Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision;
TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great
arteries.
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CHD in preterm infants have previously been reported.
9,17
Inconsistencies in definitions and denominators, as well as in
antenatal and postnatal diagnosis and management, make
more detailed comparisons difficult.
The mortality in very preterm infants with CHD has
previously been reported to vary. The lowest rate was
reported in a study of all CHDs (including minor) and the
highest rates of ≥44% have been reported in very low-birth-
weight infants (<1500 g; GA 22–29 weeks) with severe
CHD.
12,15–18
The mortality for infants born at 24 to 29 weeks’
GA in iNeo was found to be 20%, ie, less than half of that
previously reported. The lowered mortality observed in iNeo
could be related to improvements in neonatal and pediatric
cardiac care over time,
11
especially considering that the mean
GA in our report was 2 weeks lower than in the VON study
17
and similar to that in the Pediatrix study.
16
Differences in case
mix and in definitions of severe CHD may also play a role. In
VON, serious CHD was defined as any CHD treated before
discharge with specific surgical or medical therapy to correct
a major anatomic defect or a life-threatening physiologic
dysfunction
17
and not, as in iNeo, based on ICD codes
classified using EUROCAT.
29
Reassuring for very preterm infants and their families, CHD
was not associated with increased risk of major morbidity in a
majority of the models. The association with oxygen depen-
dency 36 weeks of postmenstrual age was expected and may
reflect cyanotic heart defects and heart failure rather than an
increased risk for bronchopulmonary dysplasia. An increased
risk for NEC has previously been associated with CHF caused
by a complete atrioventricular canal.
18
After adjusting for
covariates and potential confounders and also after PS
matching, the odds for NEC in the present study were not
significantly higher in infants with CHD than in those without
CHD. In the subgroup of very preterm infants with CHDs
resulting in CHF, however, we note that the NEC rate was
10.8% as compared with 4.8% in controls. This difference did
not reach statistical significance, suggesting that limitations
in power in our study may have contributed to different
conclusions.
Extremely low-birth-weight (401–1000 g) infants with any
CHD (28% with atrial or ventricular septal defects) have
previously been reported to experience higher mortality (48%)
than infants with no birth defect (35%),
15
and, in infants with
severe CHD and weighing <750 g at birth, mortality reached
79%.
16
We present the first study reporting CHD-related
mortality by each GA week in infants born very preterm
outside of the United States. Whereas mortality decreased
from 32% at 24 weeks’ GA to 1.5% at 31 weeks’ GA in infants
without severe CHD, there was much less reduction in
mortality with increasing GA in infants with CHD. The reasons
for such an uncoupling of GA and mortality in very preterm
infants are unclear. Higher proportions of outborn infants and
lower Apgar scores among infants with severe CHD than in
those without CHD may provide some clues of less active
care. However, obstetric management (treatments with
antenatal corticosteroids and cesarean section) was found
to be even more active in infants with CHD than in those
without CHD, suggesting that, at least before birth, there was
no bias towards redirection of care.
Network variations in rates of severe CHD and in outcomes
may have several explanations. The CHD incidence may vary
between populations. Variations in the use of antenatal
screening and diagnosis, in terminations of pregnancy, and in
routines for postmortem examinations may also have played a
role in incidence rates. However, high rates of antenatal
diagnosis and termination of pregnancy cannot be the only
explanation for a low postnatal incidence of severe CHDs in
very preterm infants. The highest rate of severe CHD (16.6
per 1000) was found in Sweden—a country with population-
based data, with high antenatal detection rates
37
and high
abortion rates (>50% for hypoplastic left heart syndrome or





may have been equally important for high
postnatal detection rates.
Provided the pregnancy was not terminated, an antenatal
diagnosis is likely to have improved the outcome of most
CHDs by planned delivery and perinatal management.
39
The
proportion of CHDs diagnosed before birth has been reported




but we have no
information on the specific rates for the regions and countries
participating in iNeo. Differing guidelines for centralization
and access to advanced neonatal cardiac surgery within a
reasonable time and distance may also be important in
explaining the geographical variations in outcome.
Conclusions
In very preterm infants, the added effect of a severe CHD on
mortality is pronounced, especially for infants in the upper GA
range. Still, overall, 81% of very preterm infants with severe
CHD survive the neonatal period—most of them without an
increased risk for added major neonatal morbidity. The longer-
term outcomes for these patients remain to be studied.
Appendix
Contributing International Network for Evaluation
of Outcomes in Neonates (iNeo) Site
Investigators
Australian and New Zealand Neonatal Network (ANZNN): Kei
Lui* Chair of ANZNN. Flinders Medical Centre, SA: Peter
Marshall. Gold Coast University Hospital, QLD: Peter Schmidt.
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Blacktown District Hospital, NSW: Anjali Dhawan*. John
Hunter Children’s Hospital, NSW: Paul Craven, Koert de
Waal*. King Edward Memorial and Perth Children’s Hospitals,
WA: Karen Simmer, Andy Gill*, Jane Pillow*. Liverpool
Hospital, NSW: Jacqueline Stack. Mater Mothers’ Hospital,
QLD: Pita Birch, Neonatal Retrieval Service, QLD: Lucy
Cooke*. Mercy Hospital for Women, VIC: Dan Casalaz, Jim
Holberton*. Monash Medical Centre, VIC: Alice Stewart.
Nepean Hospital, NSW: Lyn Downe. Newborn Emergency
Transport Service (VIC): Michael Stewart. NSW Pregnancy and
Newborn Services Network: Barbara Bajuk*. NSW Newborn &
Paediatric Emergency Transport Service: Andrew Berry. Royal
Children’s Hospital, VIC: Rod Hunt. Royal Darwin Hospital, NT:
Charles Kilburn. Royal Hobart Hospital, Tasmania: Tony De
Paoli. Royal Hospital for Women, NSW: Kei Lui*, Srinivas
Bolisetty. Royal North Shore Hospital, NSW: Mary Paradisis.
Royal Prince Alfred Hospital, NSW: Ingrid Rieger. Royal
Brisbane and Women’s Hospital, QLD: Pieter Koorts. Royal
Women’s Hospital, VIC: Carl Kuschel, Lex Doyle. Sydney
Children’s Hospital, NSW: Andrew Numa. The Canberra
Hospital, ACT: Hazel Carlisle. The Children’s Hospital at
Westmead, NSW: Nadia Badawi, Alison Loughran-Fowlds. The
Townsville Hospital, QLD: Guan Koh. Western Australia
Neonatal Transport Service: Jonathan Davis. Westmead
Hospital, NSW: Melissa Luig. Women’s & Children’s Hospital,
SA: Chad Andersen*. National Perinatal Epidemiology and
Statistics Unit, University of New South Wales: Georgina
Chambers*. New Zealand: Christchurch Women’s Hospital:
Nicola Austin, Adrienne Lynn. University of Otago, Christch-
urch: Brian Darlow. Dunedin Hospital: Liza Edmonds. Middle-
more Hospital: Lindsay Mildenhall. Auckland City Hospital:
Mariam Buksh, Malcolm Battin*. North Shore and Waitakere
Hospitals: Jutta van den Boom*. Waikato Hospital: David
Bourchier. Wellington Women’s Hospital: Vaughan Richard-
son, Fiona Dineen*. Singapore: KK Women’s and Children’s
Hospital, Singapore: Victor Samuel Rajadurai*. Hong Kong:
Prince of Wales Hospital: Simon Lam. United Christian
Hospital: Genevieve Fung.
*Denotes the ANZNN Executive Committee.
Canadian Neonatal Network (CNN): Prakesh S. Shah, MD,
MSc (Director, Canadian Neonatal Network and site investi-
gator), Mount Sinai Hospital, Toronto, Ontario; Adele Harrison,
MD, MBChB, Victoria General Hospital, Victoria, British
Columbia; Anne Synnes, MDCM, MHSC, and Joseph Ting,
MD, B.C. Women’s Hospital and Health Centre, Vancouver,
British Columbia; Zenon Cieslak, MD, Royal Columbian
Hospital, New Westminster, British Columbia; Rebecca Sher-
lock, MD, Surrey Memorial Hospital, Surrey, British Columbia;
Wendy Yee, MD, Foothills Medical Centre, Calgary, Alberta;
Khalid Aziz, MBBS, MA, MEd, and Jennifer Toye, MD, Royal
Alexandra Hospital, Edmonton, Alberta; Carlos Fajardo, MD,
Alberta Children’s Hospital, Calgary, Alberta; Zarin Kalapesi,
MD, Regina General Hospital, Regina, Saskatchewan; Kora-
vangattu Sankaran, MD, MBBS, and Sibasis Daspal, MD, Royal
University Hospital, Saskatoon, Saskatchewan; Mary Seshia,
MBChB, Winnipeg Health Sciences Centre, Winnipeg, Mani-
toba; Ruben Alvaro, MD, St. Boniface General Hospital,
Winnipeg, Manitoba; Amit Mukerji, MD, Hamilton Health
Sciences Centre, Hamilton, Ontario; Orlando Da Silva, MD,
MSc, London Health Sciences Centre, London, Ontario; Chuks
Nwaesei, MD, Windsor Regional Hospital, Windsor, Ontario;
Kyong-Soon Lee, MD, MSc, Hospital for Sick Children,
Toronto, Ontario; Michael Dunn, MD, Sunnybrook Health
Sciences Centre, Toronto, Ontario; Brigitte Lemyre, MD,
Children’s Hospital of Eastern Ontario and Ottawa General
Hospital, Ottawa, Ontario; Kimberly Dow, MD, Kingston
General Hospital, Kingston, Ontario; Ermelinda Pelausa, MD,
Jewish General Hospital, Montreal, Quebec; Keith Barrington,
MBChB, Hôpital Sainte-Justine, Montreal, Quebec; Christine
Drolet, MD, and Bruno Piedboeuf, MD, Centre Hospitalier
Universitaire de Quebec, Sainte Foy Quebec; Martine Claveau,
MSc, LLM, NNP, and Marc Beltempo, MD, McGill University
Health Centre, Montreal, Quebec; Valerie Bertelle, MD, and
Edith Masse, MD, Centre Hospitalier Universitaire de Sher-
brooke, Sherbrooke, Quebec; Roderick Canning, MD, Moncton
Hospital, Moncton, New Brunswick; Hala Makary, MD, Dr.
Everett Chalmers Hospital, Fredericton, New Brunswick; Cecil
Ojah, MBBS, and Luis Monterrosa, MD, Saint John Regional
Hospital, Saint John, New Brunswick; Akhil Deshpandey,
MBBS, MRCPI, Janeway Children’s Health and Rehabilitation
Centre, St. John’s, Newfoundland; Jehier Afifi, MB BCh, MSc,
IWK Health Centre, Halifax, Nova Scotia; Andrzej Kajetanow-
icz, MD, Cape Breton Regional Hospital, Sydney, Nova Scotia;
Shoo K. Lee, MBBS, PhD (Chairman, Canadian Neonatal
Network), Mount Sinai Hospital, Toronto, Ontario.
FinMBR (Finnish Medical Birth Register): Sture Andersson,
MD, Helsinki University Hospital, Helsinki; Liisa Lehtonen, MD,
Turku University Hospital, Turku; Outi Tammela, MD, Tampere
University Hospital, Tampere; Ulla Sankilampi, MD, Kuopio
University Hospital, Kuopio; Timo Saarela, MD, Oulu University
Hospital, Oulu.
Israel Neonatal Network (INN): Eli Heymann, MD, Assaf
Harofeh Medical Center, Tzrifin; Shmuel Zangen, MD, Barzilai
Medical Center, Ashkelon; Tatyana Smolkin, MD, Baruch
Padeh Medical Center, Poriya; Francis Mimouni, MD, Bikur
Cholim Hospital, Jerusalem; David Bader, MD, Bnai Zion
Medical Center, Haifa; Avi Rothschild, MD, Carmel Medical
Center, Haifa; Zipora Strauss, Chaim Sheba Medical Center,
Ramat Gan; Clari Felszer, MD, Emek Medical Center, Afula;
Hussam Omari, MD, French Saint Vincent de Paul Hospital,
Nazareth; Smadar Even Tov-Friedman, MD, Hadassah Univer-
sity Hospital-Ein Karem, Jerusalem; Benjamin Bar-Oz, MD,
Hadassah University Hospital-Har Hazofim, Jerusalem;
Michael Feldman, MD, Hillel Yaffe Medical Center, Hadera;
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Nizar Saad, MD, Holy Family (Italian) Hospital, Nazareth; Orna
Flidel-Rimon, MD, Kaplan Medical Center, Rehovot; Meir
Weisbrod, MD, Laniado Hospital, Netanya; Daniel Lubin, MD,
Mayanei Hayeshua Medical Center, Bnei Brak; Ita Litmanovitz,
MD, Meir Medical Center, Kfar Saba; Amir Kugelman, MD,
Rambam Medical Center; Eric Shinwell, MD, Rivka Ziv Medical
Center, Safed; Gil Klinger, MD, Schneider Children’s Medical
Center of Israel, Rabin Medical Center (Beilinson Campus),
Petah Tikva; Yousif Nijim, MD, Scottish (EMMS) Hospital,
Nazareth; Alona Bin-Nun, MD, Shaare-Zedek Medical Center,
Jerusalem; Agneta Golan, MD, Soroka Medical Center, Beer-
sheba; Dror Mandel, MD, Sourasky Medical Center, Tel Aviv;
Vered Fleisher-Sheffer, MD,Western Galilee Medical Center,
Nahariya; David Kohelet, MD, Wolfson Medical Center, Holon;
Lev Bakhrakh, MD, Yoseftal Hospital, Eilat.
Neonatal Research Network Japan (NRNJ): Satoshi Hattori,
MD, Sapporo City Hospital, Sapporo, Hokkaido; Masaru Shirai,
MD Asahikawa Kosei Hospital, Asahikawa, Hokkaido; Toru
Ishioka, MD, Engaru Kosei Hospital, Engaru, Hokkaido;
Toshihiko Mori, MD NTT East Sappro Hospital, Sapporo,
Hokkaido; Takasuke Amizuka, MD, Aomori Prefecture Central
Hospital, Aomori, Aomori; Toru Huchimukai, MD, Iwate
Prefecture Ohfunato Hospital, Ofunato, Iwate; Hiroshi
Yoshida, MD, Tsuruoka City Shonai Hospital, Tsuruoka,
Yamagata; Ayako Sasaki, MD, Yamagata University, Yama-
gata, Yamagata; Junichi Shimizu, MD, Tsuchiura Kyodo
Hospital, Tsuchiura, Ibaraki; Toshihiko Nakamura, MD,
National Nishisaitama Central Hospital, Tokorozawa, Saitama;
Mami Maruyama, MD, Jichi Medical University Saitame
Medical Center, Omiya, Saitama; Hiroshi Matsumoto, MD,
Asahi Central Hospital, Asahi, Chiba; Shinichi Hosokawa, MD,
National International Medical Center, Shinjuku, Tokyo;
Atsuko Taki, MD, Tokyo Medical and Dental University,
Bunkyo, Tokyo; Machiko Nakagawa, MD, Saint Luku Hospital,
Chuo, Tokyo; Kyone Ko, MD, Sanikukai Hospital, Sumida,
Tokyo; Azusa Uozumi, MD, Odawara City Hospital, Odawara,
Kanagawa; Setsuko Nakata, MD, Iida City Hospital, Iida,
Nagano; Akira Shimazaki, MD, National Shinshu Ueda Medical
Center, Ueda, Nagano; Tatsuya Yoda, MD, Saku General
Hospital, Saku, Nagano; Osamu Numata, MD, Nagaoka Red
Cross Hospital, Nagaoka, Niigata; Hiroaki Imamura, MD,
Koseiren Takaoka Hospital, Takaoka, Toyama; Azusa Kobaya-
shi, MD, Kanazawa Medical University, Kanazawa, Kanazawa;
Shuko Tokuriki, MD, Fukui University, Fukui, Fukui; Yasushi
Uchida, MD, National Nagara Medical Center, Nagara, Gifu;
Takahiro Arai, MD, Takayama Red Cross Hospital, Takayama,
Gifu; Mitsuhiro Ito, MD, Fujieda City Hospital, Fujieda,
Shizuoka; Kuniko Ieda, MD, Koritsu Tosei Hospital, Toyota,
Aichi; Toshiyuki Ono, MD, Komaki City Hospital, Komaki, Aichi;
Masashi Hayashi, MD, Okazaki City Hospital, Okazaki, Aichi;
Kanemasa Maki, MD, Yokkaichi City Hospital, Yokkaichi,
MieToru Yamakawa, MD, Japan Baptist Hospital, Kyoto, Kyoto;
Masahiko Kawai, MD, Kyoto University, Kyoto, Kyoto; Noriko
Fujii, MD, Fukuchiyama City Hospital, Fukuchiyama, Kyoto;
Kozue Shiomi, MD, Kyoto City Hospital, Kyoto, Kyoto; Koji
Nozaki, MD, Mitubishi Kyoto Hospital, Kyoto, Kyoto; Hiroshi
Wada, MD, Yodogawa Christian Hospital, Osaka, Osaka; Taho
Kim, MD, Osaka City Sumiyoshi Hospital, Osaka, Osaka;
Yasuyuki Tokunaga, MD, Toyonaka City Hospital, Toyonaka,
Osaka and National Cerebral and Cardiovascular Center,
Suita, Osaka; Akihiro Takatera, MD, Chifune Hospital, Osaka,
Osaka; Toshio Oshima, MD, Bell Land General Hospital, Sakai,
Osaka; Hiroshi Sumida, MD, Rinku General Hospital, Izu-
misano, Osaka; Yae Michinomae, MD, Yao City Hospital, Yao,
Osaka; Yoshio Kusumoto, MD, Osaka General Medical Center,
Osaka, Osaka; Seiji Yoshimoto, MD Kobe Children’s Hospital,
Kobe, Hyogo; Takeshi Morisawa, MD, Kakogawa City Hospital,
Kakogawa, Hyogo; Tamaki Ohashi, MD, Hyogo Prefectural
Awaji Hospital, Sumoto, Hyogo; Yukihiro Takahashi, MD, Nara
Prefecture Medical University, Kashiwara, Nara; Moriharu
Sugimoto, MD, Tsuyama Central Hospital, Tsuyama, Okayama;
Noriaki Ono, MD, Hiroshima University, Hiroshima, Hiroshima;
Shinichiro Miyagawa, MD National Kure Medical Center, Kure,
Hiroshima; Takahiko Saijo, MD, Tokushima University,
Tokushima, Tokushima; Takashi Yamagami, MD, Tokushima
City Hospital, Tokushima, Tokushima; Kosuke Koyano, MD,
Kagawa University, Kida, Kagawa; Shoko Kobayashi, MD,
Shikoku Medical Center for Children and Adults, Zentsuji,
Kagawa; Takeshi Kanda, MD, National Kyushu Medical Center,
Fukuoka, Fukuoka; Yoshihiro Sakemi, MD, National Kokura
Medical Center, Kitakyushu, Fukuoka; Mikio Aoki, MD,
National Nagasaki Medical Center, Nagasaki, Nagasaki; Koichi
Iida, MD, Oita Prefectural Hospital, Oita, Oita; Mitsushi Goshi,
MD, Nakatsu City Hospital, Nakatsu, Oita; Yuko Maruyama,
MD, Imakyure General Hospital, Kagoshima, Kagoshima.
Spanish Neonatal Network (SEN1500): Alejandro Avila-
Alvarez, MD, and Jose Luis Fernandez-Trisac, MD, Complexo
Hospitalario Universitario De A Coru~na, A Coru~na; Mª Luz Couce
Pico, MD, andMarıa Jose Fernandez Seara, MD, Hospital Clınico
Universitario de Santiago, Santiago de Compostela; Andres
Martınez Gutierrez, MD, Complejo Hospitalario Albacete,
Albacete; Carolina Vizcaıno, MD, Hospital General Universitario
de Elche, Alicante; Miriam Salvador Iglesias, MD, and Honorio
Sanchez Zaplana, MD, Hospital General Universitario de
Alicante, Alicante; Belen Fernandez Colomer, MD, and Jose
Enrique Garcıa Lopez, MD, Hospital Universitario Central de
Asturias, Oviedo, Asturias; Rafael Garcıa Mozo, MD, and M.
Teresa Gonzalez Martınez, MD, Hospital Universitario de
Cabue~nes, Gijon, Asturias; Mª Dolores Muro Sebastian, MD,
and Marta Balart Carbonell, MD, Clınica Corachan, Barcelona;
Joan Badia Barnusell, MD, and Monica Domingo Puiggros, MD,
Corporacio Parc Taulı, Sabadell, Barcelona; Josep Figueras Aloy,
MD, and Francesc Botet Mussons, MD, Hospital Clınic de
Barcelona, Barcelona; Israel Anquela Sanz, MD, Hospitalario De
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Granollers, Granollers; Gemma Ginovart Galiana, MD, H. De La
Santa Creu I Sant Pau, Barcelona; W. Coroleu, MD, Hospital
Universitari Germans Trias I Pujol, Badalona; Martin Iriondo,
MD, Hospital Sant Joan de Deu Barcelona, Esplugues de
Llobregat, Barcelona; Laura Castells Vilella, MD, Hospital
General de Catalu~na, Barcelona; Roser Porta, MD, Institute
Dexeus, Barcelona; Xavier Demestre, MD, and Silvia Martınez
Nadal, MD, Scias-Hospital Barcelona, Barcelona; Cristina de
Frutos Martınez, MD, Hospital Universitario de Burgos, Burgos;
Marıa Jesus Lopez Cuesta, MD, H. San Pedro de Alcantara,
Caceres; Dolores Esquivel Mora, MD, and Joaquın Ortiz Tardıo,
MD, Hospital Jerez, Cadiz; Isabel Benavente, MD, and Almudena
Alonso, MD, Hospital Universitario Puerta Del Mar, Cadiz;
Ramon Aguilera Olmos, MD, Hospital General de Castellon,
Castellon; Miguel A. Garcıa Cabezas, MD, and Mª Dolores
Martınez Jimenez,MD, Hospital General Universitario de Ciudad
Real, Ciudad Real; Mª Pilar Jaraba Caballero,MD, andMªDolores
Ordo~nez Dıaz, MD, Hospital Universitario Reina Sofıa, Cordoba;
Alberto Trujillo Fagundo, MD, and Lluis Mayol Canals, MD,
Hospital Universitari de Girona Dr. Josep Trueta, Girona; Fermın
Garcıa-Mu~noz Rodrigo, MD, and Lourdes Urquıa Martı, MD,
H.M.I. Las Palmas, Las Palmas, Gran Canaria; Marıa Fernanda
Moreno Galdo, MD, and Jose Antonio Hurtado Suazo, MD,
Hospital Universitario Virgen De Las Nieves, Granada; Eduardo
Narbona Lopez, and Jose Uberos Fernandez, MD, Hospital
Universitario San Cecilio, Granada; Miguel A. Cortajarena
Altuna, MD, and Oihana Muga Zuriarrain Hospital, MD, Donos-
tia, Gipuzkoa; David Mora Navarro, MD, Hospital Juan Ramon
Jimenez, Huelva; Marıa Teresa Domınguez, MD, Hospital Costa
De La Luz, Huelva; Mª Yolanda Ruiz del Prado, MD, and Ines
Esteban Dıez, MD, Hospital San Pedro, Logro~no, La Rioja; Marıa
Teresa Palau Benavides, MD, and Santiago Lape~na, MD,
Hospital de Leon, Leon, Leon; Teresa Prada, MD, Hospital del
Bierzo, Ponferrada, Leon; Eduard Soler Mir, MD, Hospital Arnau
De Vilanova, Lleida; Araceli Corredera Sanchez, MD, Enrique
Criado Vega, MD, Nayade del Prado, MD, and Cristina
Fernandez, MD, Hospital Clınico San Carlos, Madrid; Lucıa
Cabanillas Vilaplana, MD, and Irene Cuadrado Perez, MD,
Hospital Universitario De Getafe, Madrid; Luisa Lopez Gomez,
MD, Hospital De La Zarzuela, Madrid; Laura Domingo Comeche,
MD, Hospital Universitario de Fuenlabrada, Fuenlabrada,
Madrid; Isabel LlanaMartın, MD, Hospital Madrid-Torrelodones,
Madrid, Madrid; Carmen Gonzalez Armengod, MD, and Carmen
Mu~noz Labian, MD, Hospital Universitario Puerta De Hierro,
Majadahonda, Madrid; Mª Jose Santos Mu~noz, MD, Hospital
Severo Ochoa, Leganes, Madrid; Dorotea Blanco Bravo, MD,
and Vicente Perez, MD, Hospital Gregorio Mara~non, Madrid; Mª
Dolores Elorza Fernandez, MD, Celia Dıaz Gonzalez, MD, and
Susana Ares Segura, MD, H.U. La Paz, Madrid; Manuela Lopez
Azorın, MD, Hospital Universitario Quironsalud Madrid, Madrid;
Ana Belen Jimenez MD, Hospital Universitario Fundacion
Jimenez Dıaz, Madrid; Tomas Sanchez-Tamayo, MD, and Elıas
Tapia Moreno, MD, Hospital Carlos Haya, Malaga; Marıa
Gonzalez, MD, and Jose Enrique Sanchez Martınez, MD,
Hospital Parque San Antonio De Malaga, Malaga; Jose Marıa
Lloreda Garcıa, MD, Hospital Universitario Santa Lucia De
Cartagena, Murcia; Concepcion Go~ni Orayen, MD, Hospital
Virgen Del Camino De Pamplona, Pamplona, Navarra; Javier
Vilas Gonzalez, MD, Complexo Hospitalario Pontevedra, Pon-
tevedra; Marıa Suarez Albo, MD, and Eva Gonzalez Colmenero,
MD, Hospital Xeral De Vigo, Pontevedra; Elena Pilar Gutierrez
Gonzalez, MD, and Beatriz Vacas del Arco, MD, Hospital
Universitario de Salamanca, Salamanca; Josefina Marquez
Fernandez, MD, and Laura Acosta Gordillo, MD, Hospital Valme,
Sevilla; Mercedes Granero Asensio, MD, Hospital Virgen De La
Macarena, Sevilla; Carmen Macıas Dıaz, MD, Hospital Univer-
sitario Virgen Del Rocıo, Sevilla; Mar Albujar, MD, Hospital
Universitari de Tarragona Joan XXIII, Tarragona; Pedro Fuster
Jorge, MD, Hospital Universitario De Canarias, San Cristobal de
La Laguna, Santa Cruz de Tenerife; Sabina Romero, MD, and
Monica Rivero Falero, MD, Hospital Universitario Nuestra
Se~nora De Candelaria, Santa Cruz de Tenerife; Ana Belen
Escobar Izquierdo, Hospital Virgen De La Salud, Toledo; Javier
Esta~n Capell, MD, Hospital Clinico Universitario De Valencia,
Valencia; Mª Isabel Izquierdo Macian, MD, Hospital Universitari
La Fe, Valencia; Mª Mar Montejo Vicente, MD, and Raquel
Izquierdo Caballero, MD, Hospital Universitario Rıo Hortega,
Valladolid; MªMercedes Martınez, MD, and Aintzane Euba, MD,
Hospital de Txagorritxu, Vitoria-Gasteiz; Amaya Rodrıguez
Serna, MD, and Juan Marıa Lopez de Heredia Goya, MD,
Hospital de Cruces, Baracaldo; Alberto Perez Legorburu, MD,
and Ana Gutierrez Amoros, MD, Hospital Universitario de
Basurto, Bilbao; Vıctor Manuel Marugan Isabel, MD, and Natalio
Hernandez Gonzalez, MD, Hospital Virgen De La Concha—
Complejo Asistencial De Zamora, Zamora; Segundo Rite Gracia,
MD, Hospital Miguel Servet, Zaragoza; Mª Purificacion Ventura
Faci, MD, and Mª Pilar Samper Villagrasa, MD, Hospital Clınico
Universitario Lozano Blesa, Zaragoza.
SNQ (Swedish Neonatal Quality Register): Jiri Kofron, MD,
S€odra €Alvsborgs Sjukhus, Boras; Katarina Strand Brodd, MD,
M€alarsjukhuset, Eskilstuna; Andreas Odlind, MD, Falu Lasarett,
Falun; Lars Alberg, MD, G€allivare Sjukhus, G€allivare; Sofia
Arwehed, MD, G€avle Sjukhus, G€avle; Ola Hafstr€om, MD, SU/€O
stra, G€oteborg; Anna Kasemo, MD, L€anssjukhuset, Halmstad;
Karin Nederman, MD, Helsingborgs Lasarett, Helsingborg; Lars
Ahman, MD, Hudiksvalls Sjukhus, Hudiksvall; Fredrik Inge-
marsson, MD, L€anssjukhuset Ryhov, J€onk€oping; Hen-
rik Petersson, MD, L€anssjukhuset, Kalmar; Pernilla Thurn, MD,
Blekingesjukhuset, Karlskrona; Eva Albinsson, MD,
Centralsjukhuset, Karlstad; Bo Selander, MD, Centralsjukhuset,
Kristianstad;ThomasAbrahamsson,MD,Universitetssjukhuset,
Link€oping; Ingela Heimdahl, MD, Sunderby sjukhus, Lulea;
Kristbjorg Sveinsdottir, MD, Skanes Universitetssjukhus,
Malm€o/Lund; Erik Wejryd, MD, Vrinnevisjukhuset, Norrk€oping;
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Anna Hedlund, MD, Skelleftea Lasarett, Skelleftea; Maria
Katarina S€oderberg, MD, K€arnsjukhuset Skaraborg, Sk€ovde;
Lars Naver, MD, Karolinska Sjukhuset, Stockholm; Thomas
Brune, MD, S€odersjuhuset, Stockholm; Jens B€ackstr€om, MD,
L€anssjukhuset, Sundsvall; JohanRobinson,MD,Norra €Alvsborgs
L€anssjukhus, Trollh€attan; Aijaz Farooqi, MD, Norrlands Univer-
sitetssjukhus, Umea; Erik Normann, MD, Akademiska Barn-
sjukhuset, Uppsala; Magnus Fredriksson, MD, Visby Lasarett,
Visby; Anders Palm, MD, V€asterviks Sjukhus, V€astervik; Urban
Rosenqvist, MD, Centrallasarettet, V€asteras; Bengt Walde, MD,
Centrallasarettet, V€axj€o;CeciliaHagman,MD, Lasarettet, Ystad;
Andreas Ohlin, MD, Universitetssjukhuset, €Orebro; Rein Florell,
MD, €Ornsk€oldsviks Sjukhus, €Ornsk€oldsvik; Agneta Smedsaas-
L€ofvenberg, MD, €Ostersunds Sjukhus, €Ostersund.
Switzerland Neonatal Network (SwissNeoNet): Mark Adams,
PhD (Network coordinator), University Hospital Zurich; Philipp
Meyer, MD, and Rachel Kusche, MD, Cantonal Hospital,
Children’s Clinic, Aarau; Sven Schulzke, MD, University
Children’s Hospital, Basel; Mathias Nelle, MD, University
Hospital, Berne; Bendicht Wagner, MD, University Hospital,
Berne; Thomas Riedel, MD, Children’s Hospital, Chur; Gregoire
Kaczala, MD, Cantonal Hospital, Fribourg; Riccardo E. Pfister,
MD, University Hospital (HUG), Geneva; Jean-Francois Tolsa,
MD, and Matthias Roth, MD, University Hospital (CHUV),
Lausanne; Martin Stocker, MD, Children’s Hospital, Lucerne;
Bernhard Laubscher, MD, Cantonal Hospital, Neuchatel;
Andreas Malzacher, MD, Cantonal Hospital, St. Gallen; John
P. Micallef, MD, Children’s Hospital, St. Gallen; Lukas Hegi,
MD, Cantonal Hospital, Winterthur; Dirk Bassler, MD, and
Romaine Arlettaz, MD, University Hospital (USZ), Zurich; Vera
Bernet, MD, University Children’s Hospital, Zurich.
Toscane on-line Network (TIN): Carlo Dani, MD, Careggi
University Hospital, Florence, Italy; Patrizio Fiorini, MD, Anna
Meyer Children’s University Hospital, Florence, Italy; Paolo
Ghirri, MD, University Hospital of Pisa, Pisa, Italy; Barbara
Tomasini, MD, University Hospital of Siena, Siena, Italy.
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